UH3NCT05995535
Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 6 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
Stopped Trial terminated Sponsor's reason: mid analysis showed futility Show 5 more changesShow less
- Start date: Jan 1, 2024 to Sep 1, 2024
- Eligibility criteria expanded, about 28 words
- Final enrollment: 112 participants (planned 150)
- Interventions: LFX/PGB (Drug), LFX/PLA-PGB (Drug) to LFX/PGB (Drug), LFX/PLA-PGB (Drug)
- Site details revised at 2 of 2 sites
- Minor Site contacts updated at 2 of 2 sitesv6
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 1 to 2
- Notable Start date: Nov 1, 2023 to Jan 1, 2024v4
- Notable Start date: Sep 1, 2023 to Nov 1, 2023v3
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Subjective Opioid Withdrawal Scale (SOWS) scores
Timeframe: 10 days per subject, through study completion (N=150)
Secondary (2)
Study detox completion
XR-NTX IM injection
Arms and interventions
LFX/PGBExperimental
PGB/day 1=400mg, day 2-7=600mg each day, day 8=400mg, day 9=200mg, day 10=100mg LFX/day 1=1.62mg, day 2-7=2.16mg each day, day 8=1.44mg, day 9=0.72mg, day 10=0.72mg
LFX/PLA-PGBActive comparator
PLA-PGB/day 1-7= 0mg each day, day 8, 9, and 10 =0mg each day LFX/ day 1=1.62mg, day 2-7=2.16mg each day, day 8=1.44mg, day 9=0.72mg, day 10=0.72mg
Drugs: LFX/PGB, LFX/PLA-PGB
Sites
2 sites in 1 country